Results 41 to 50 of about 8,734 (193)

IMGT® Biocuration and Analysis of the Rhesus Monkey IG Loci

open access: yesVaccines, 2022
The adaptive immune system, along with the innate immune system, are the two main biological processes that protect an organism from pathogens. The adaptive immune system is characterized by the specificity and extreme diversity of its antigen receptors.
Viviane Nguefack Ngoune   +10 more
doaj   +1 more source

Ontology for immunogenetics: the IMGT-ONTOLOGY [PDF]

open access: yesBioinformatics, 1999
Abstract Motivation: IMGT, the international ImMunoGene- Tics database (http://imgt.cines.fr:8104), created by M.-P. Lefranc, is an integrated database specializing in antigen receptors (immunoglobulins and T-cell receptors) and major histocompatibility complex (MHC) of all vertebrate species.
Véronique Giudicelli   +1 more
openaire   +3 more sources

IMGT® Biocuration and Comparative Study of the T Cell Receptor Beta Locus of Veterinary Species Based on Homo sapiens TRB

open access: yesFrontiers in Immunology, 2020
IMGT®, the international ImMunoGeneTics information system® is the global reference in immunogenetics and immunoinformatics. By its creation in 1989 by Marie-Paule Lefranc (Université de Montpellier and CNRS), IMGT® marked the advent of immunoinformatics,
Perrine Pégorier   +10 more
doaj   +1 more source

Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2019
Background: Polymorphism within the human T-cell receptor beta variable (TRBV) gene has been proposed as a risk factor for autoimmune disease and immune-related adverse events (IRAEs) during immunotherapy.
Timothy J Looney   +20 more
doaj   +1 more source

IgMAT: immunoglobulin sequence multi-species annotation tool for any species including those with incomplete antibody annotation or unusual characteristics

open access: yesBMC Bioinformatics, 2023
Background The advent and continual improvement of high-throughput sequencing technologies has made immunoglobulin repertoire sequencing accessible and informative regardless of study species. However, to fully map dynamic changes in polyclonal responses
Daniel Dorey-Robinson   +2 more
doaj   +1 more source

IG and TR single chain fragment variable (scFv) sequence analysis: a new advanced functionality of IMGT/V-QUEST and IMGT/HighV-QUEST

open access: yesBMC Immunology, 2017
Background IMGT®, the international ImMunoGeneTics information system® ( http://www.imgt.org ), was created in 1989 in Montpellier, France (CNRS and Montpellier University) to manage the huge and complex diversity of the antigen receptors, and is at the ...
Véronique Giudicelli   +3 more
doaj   +1 more source

PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models

open access: yesPharmaceuticals, 2020
Cancer immunotherapy has revolutionized the way different neoplasms are treated. Among the different variations of cancer immunotherapy, the checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis
Daehyun Kim   +4 more
doaj   +1 more source

Recovering probabilities for nucleotide trimming processes for T cell receptor TRA and TRG V-J junctions analyzed with IMGT tools

open access: yesBMC Bioinformatics, 2008
Background Nucleotides are trimmed from the ends of variable (V), diversity (D) and joining (J) genes during immunoglobulin (IG) and T cell receptor (TR) rearrangements in B cells and T cells of the immune system. This trimming is followed by addition of
Lefranc Marie-Paule   +2 more
doaj   +1 more source

A BALB/c IGHV Reference Set, Defined by Haplotype Analysis of Long-Read VDJ-C Sequences From F1 (BALB/c x C57BL/6) Mice

open access: yesFrontiers in Immunology, 2022
The immunoglobulin genes of inbred mouse strains that are commonly used in models of antibody-mediated human diseases are poorly characterized. This compromises data analysis.
Katherine J. L. Jackson   +11 more
doaj   +1 more source

A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma

open access: yesMedComm, Volume 7, Issue 7, July 2026.
This phase II trial suggests the potential of perioperative camrelizumab plus neoadjuvant chemotherapy in patients with resectable stage IIB‐IIIB lung squamous cell carcinoma. The major pathological response rate (primary endpoint) was 60.0%, and the pathological complete response (pCR) rate was 44.4%.
Mingming Hu   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy